AR036236A1 - Inhibidores del mecanismo de intercambio na+/ca2+ y metodo para la inhibicion del mecanismo de intercambio na+/ca2+ en celulas y para el tratamiento de arritmias - Google Patents

Inhibidores del mecanismo de intercambio na+/ca2+ y metodo para la inhibicion del mecanismo de intercambio na+/ca2+ en celulas y para el tratamiento de arritmias

Info

Publication number
AR036236A1
AR036236A1 ARP020102586A ARP020102586A AR036236A1 AR 036236 A1 AR036236 A1 AR 036236A1 AR P020102586 A ARP020102586 A AR P020102586A AR P020102586 A ARP020102586 A AR P020102586A AR 036236 A1 AR036236 A1 AR 036236A1
Authority
AR
Argentina
Prior art keywords
independently
acyl
exchange mechanism
lower alkyl
inhibitors
Prior art date
Application number
ARP020102586A
Other languages
English (en)
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR036236A1 publication Critical patent/AR036236A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Compuestos con actividad terapéutica de la fórmula (1), donde X es -O-, -CH2- o -C(O)-; Z es -CHR9- o un enlace de valencia; Y es -CH2-, -C(O)-, CH(OR10)-, -CH(NR11R12)-, -O-, -S-, -S(O)- o -S(O)2- con la salvedad de que cuando Z es un enlace de valencia, Y no es C(O); la línea punteada representa una doble ligadura optativa en cuyo caso Z es -CR9- e Y es -CH-, C(OR10)- o C(NR11R12)-; R1 es -(CH2)nNR4R7 o uno de los grupos: (2), (3) (4); n es 1 - 4; R2 y R3 son independientemente H, alquilo inferior, alcoxi inferior, -NO2, halógeno,-CF3, -OH, -NHR8 ó -COOH; R4 y R7 son independientemente H, alquilo inferior o hidroxialquilo inferior; R5 es H, alcoxi inferior, -CF3, -NH2 ó -CN; R6 es -NO2, NR14R19, -CF3, o de fórmula (5); R8 y R16 son independientemente H o acilo; R9 es H o alquilo inferior; R10 es H, alquilsulfonilo o acilo; R11 y R12 son independientemente H, alquilo inferior o acilo; R13 y R18 son independientemente H ó -OR20; R14 y R19 son independientemente H, acilo, alquilsulfonilo, C(S)NHR17 ó C(O)NHR17; R15 es H o NH2; R17 es H o alquilo inferior; R20 es H o acilo; y sus sales y ésteres aceptables para uso farmacéutico. Los compuestos son potentes inhibidores del mecanismo de intercambio de Na+/Ca2+.
ARP020102586A 2001-07-10 2002-07-10 Inhibidores del mecanismo de intercambio na+/ca2+ y metodo para la inhibicion del mecanismo de intercambio na+/ca2+ en celulas y para el tratamiento de arritmias AR036236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20011507A FI20011507A0 (fi) 2001-07-10 2001-07-10 Uusia yhdisteitä

Publications (1)

Publication Number Publication Date
AR036236A1 true AR036236A1 (es) 2004-08-25

Family

ID=8561628

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102586A AR036236A1 (es) 2001-07-10 2002-07-10 Inhibidores del mecanismo de intercambio na+/ca2+ y metodo para la inhibicion del mecanismo de intercambio na+/ca2+ en celulas y para el tratamiento de arritmias

Country Status (28)

Country Link
US (1) US7425568B2 (es)
EP (1) EP1412343B1 (es)
JP (1) JP4113839B2 (es)
KR (1) KR20040025697A (es)
CN (1) CN1281597C (es)
AR (1) AR036236A1 (es)
AT (1) ATE338038T1 (es)
AU (1) AU2002321339B2 (es)
BR (1) BR0211070A (es)
CA (1) CA2452918C (es)
DE (1) DE60214388T2 (es)
DK (1) DK1412343T3 (es)
EA (1) EA006580B1 (es)
ES (1) ES2269746T3 (es)
FI (1) FI20011507A0 (es)
HK (1) HK1068611A1 (es)
HR (1) HRP20040133A2 (es)
HU (1) HUP0400391A3 (es)
IL (2) IL159647A0 (es)
MX (1) MXPA04000267A (es)
NO (1) NO20035821L (es)
NZ (1) NZ530490A (es)
PL (1) PL367958A1 (es)
PT (1) PT1412343E (es)
RS (1) RS50886B (es)
UA (1) UA76168C2 (es)
WO (1) WO2003006452A1 (es)
ZA (1) ZA200400145B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
DK1856085T3 (en) 2005-03-11 2015-10-05 Howard Florey Inst Pty Ltd FLAVONOID COMPOUNDS AND APPLICATIONS THEREOF
SI2567958T1 (sl) 2011-09-12 2015-01-30 Sanofi Substituirani 2-(kroman-6-iloksi)-tiazoli in njihova uporaba kot farmacevtiki
AU2011376746B2 (en) * 2011-09-12 2017-06-15 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
US8912224B2 (en) 2011-09-12 2014-12-16 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
JP5941637B2 (ja) * 2011-09-12 2016-06-29 サノフイ 置換２−（クロマン−６−イルオキシ）−チアゾール及び医薬としてのその使用
CN102993195B (zh) * 2011-09-14 2017-05-17 赛诺菲 取代的2‑(色满‑6‑基氧基)噻唑及其作为药物的用途
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
TWI633095B (zh) * 2013-03-08 2018-08-21 賽諾菲公司 經取代－６－基氧基－環烷類及其作為醫藥品之用途
GB201416186D0 (en) 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
WO2019175464A1 (en) 2018-03-14 2019-09-19 Orion Corporation Compounds useful as inhibitors of sodium-calcium exchanger (ncx)
CA3187514A1 (en) 2020-07-28 2022-02-03 Andrew BELFIELD Fused bicyclic raf inhibitors and methods for use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820817A (en) 1954-02-04 1958-01-21 Mcneilab Inc Oxygenated indan compounds and method of making the same
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
BE650081A (es) 1963-07-03
GB1154119A (en) 1968-05-20 1969-06-04 Merck Ag E 3-Alkyl-Flavanones
FR2733685B1 (fr) 1995-05-05 1997-05-30 Adir Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant
JPH0967336A (ja) 1995-09-04 1997-03-11 Kanebo Ltd 新規なイソチオウレア誘導体
DE69810606T2 (de) 1997-03-27 2003-10-09 Taisho Pharmaceutical Co., Ltd. 2-phenoxyanilinderivate
JPH1149752A (ja) 1997-08-05 1999-02-23 Taisho Pharmaceut Co Ltd フェノキシピリジン誘導体
DE19742508A1 (de) 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
ATE231487T1 (de) 1997-10-20 2003-02-15 Taisho Pharmaceutical Co Ltd 2-phenoxyanilin-derivate
JPH11302235A (ja) 1998-04-15 1999-11-02 Taisho Pharmaceut Co Ltd フェノキシアルキルアミン誘導体
EP1180029A4 (en) 1999-04-23 2002-10-02 Bristol Myers Squibb Co BICYCLIC ACYL IHIBITORING SODIUM / PROTON EXCHANGER AND RELATED PROCEDURE.
NZ517404A (en) 1999-09-17 2003-01-31 Nissan Chemical Ind Ltd Benzopyran derivative
FI20030030A0 (fi) 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä

Also Published As

Publication number Publication date
JP2005504738A (ja) 2005-02-17
CA2452918A1 (en) 2003-01-23
US7425568B2 (en) 2008-09-16
PT1412343E (pt) 2006-12-29
IL159647A (en) 2008-04-13
DE60214388D1 (de) 2006-10-12
CN1281597C (zh) 2006-10-25
CN1525966A (zh) 2004-09-01
HUP0400391A3 (en) 2008-03-28
ES2269746T3 (es) 2007-04-01
EA200400161A1 (ru) 2004-06-24
EP1412343A1 (en) 2004-04-28
JP4113839B2 (ja) 2008-07-09
RS50886B (sr) 2010-08-31
RS604A (en) 2006-12-15
BR0211070A (pt) 2004-06-15
HK1068611A1 (en) 2005-04-29
EP1412343B1 (en) 2006-08-30
EA006580B1 (ru) 2006-02-24
DK1412343T3 (da) 2007-01-02
HUP0400391A2 (hu) 2004-12-28
PL367958A1 (en) 2005-03-07
MXPA04000267A (es) 2004-07-23
CA2452918C (en) 2010-02-16
HRP20040133A2 (en) 2004-08-31
NZ530490A (en) 2005-12-23
UA76168C2 (en) 2006-07-17
NO20035821L (no) 2004-02-24
ZA200400145B (en) 2005-04-08
IL159647A0 (en) 2004-06-01
KR20040025697A (ko) 2004-03-24
AU2002321339B2 (en) 2007-06-21
FI20011507A0 (fi) 2001-07-10
US20040235905A1 (en) 2004-11-25
WO2003006452A1 (en) 2003-01-23
DE60214388T2 (de) 2007-09-13
ATE338038T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
AR036236A1 (es) Inhibidores del mecanismo de intercambio na+/ca2+ y metodo para la inhibicion del mecanismo de intercambio na+/ca2+ en celulas y para el tratamiento de arritmias
AR042733A1 (es) Derivados de piridinas utilizados como inhibidores del mecanismo de intercambio na+/ca2+
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
BR9813360A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz (mmp)
AR042438A1 (es) Derivados de fluorglicosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
NO20084390L (no) Substituerte naftylindol-derivater som inhibitorer av plasminogen-aktivatorinhibitor type-1 (PAI-1)
CR7865A (es) Derivados de dihidropiranoindol -3,4-diona sustituidos y derivados de 2-hidroximetilindol del acido 3-oxoacetico sustituidos como inhibidores del inhibidor del activador del plasminogeno 1(pai-1)
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
SE9503022D0 (sv) Alkoxifenylsubstituerade bisacylfosfinoxider
AR009020A1 (es) Inhibidores de proteasas
ES2266459T3 (es) Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia.
AR027402A1 (es) Derivados de pirimidina.
CO5261625A1 (es) Novedoso derivados fenilheteroalquilamina, procesos para su prepraracion, coposiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
AR011134A1 (es) Derivados de imidazo piridina substituidos para la inhibicion de la secrecion de acido gastrico; una sal del mismo, procedimiento para su preparacion, formulacion farmaceutica que los contiene y el uso de dicho compuesto para la manufactura de un medicamento
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
ATE346067T1 (de) Carbolinderivate
ATE332903T1 (de) Kondensierte pyridoindolderivate
AR040339A1 (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas
AR039689A1 (es) Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso
ES2181153T3 (es) Compuestos de triazinilaminoestilbeno.
AR032778A1 (es) Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento
CY1105411T1 (el) Νεα παραγωγα πλευρομουτιλινης
ES2071325T3 (es) Derivados de 4-alquilimidazol.
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
AR013462A1 (es) Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos

Legal Events

Date Code Title Description
FB Suspension of granting procedure